CGEN

#3075
Compugen Ltd. - Ordinary Shares
2.6 3 USD
-5.40%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
2.63
2.63
Year Range
1.32
3.24
Daily Change
-5.40%
Monthly Change
+0.38%
6 month change
+67.52%
Year Change
+69.68%
Previous Close
2.7 8
Open
2.6 3
Low
2.6 3
High
2.6 3
Volume
11
Open full chart Full chart

Financials

Overview Statement Statistics
Quarterly Annual
  • Market Capitalization 248.67 M
  • Employee 75
  • Founded 1993
  • CEO Anat Cohen-Dayag
  • Website www.cgen.com
  • Headquarter Israel
  • FIGI UNKNOWN
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
4.03
Price to sales ratio
1.97

Compugen Ltd. - Ordinary Shares

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

News